Discounted Cash Flow
Phathom Pharmaceuticals, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2018 | — | $-1.3m | $-36.5m | — | $-0.21 |
| 2019 | — | $-255.1m (-19708.3%) | $-69.8m (-91.2%) | — | $-22.45 (-10590.5%) |
| 2020 | — | $-129.1m (49.4%) | $-149.7m (-114.3%) | — | $-3.88 (82.7%) |
| 2021 | — | $-143.9m (-11.5%) | $-146.9m (1.9%) | — | $-3.89 (-0.3%) |
| 2022 | $0 | $-197.7m (-37.4%) | $-138.6m (5.6%) | — | $-5.05 (-29.8%) |
| 2023 | $682.0k | $-201.6m (-2.0%) | $-268.4m (-93.6%) | -29558.9% | $-3.93 (22.2%) |
| 2024 | $55.3m (8001.5%) | $-334.3m (-65.8%) | $-166.9m (37.8%) | -605.1% (98.0%) | $-5.29 (-34.6%) |
| 2025 | $175.1m (216.9%) | $-221.2m (33.8%) | $-167.0m (-0.1%) | -126.3% (79.1%) | $-3.03 (42.7%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.